CP-195543

CP‑195543 is a structurally novel, selective and potent small molecule antagonist of the leukotriene B₄ receptor (LTB₄R). It was developed by Pfizer for the treatment of inflammatory diseases such as rheumatoid arthritis. The drug inhibits human and mouse neutrophil chemotaxis mediated by LTB₄ and blocks LTB₄-mediated neutrophil infiltration in animal models. In clinical development, it was evaluated in combination with celecoxib for rheumatoid arthritis but failed to show superiority over placebo; its development was subsequently discontinued[1][3][5].

Other names

204981-48-6UNII-YB1F0V77MKUNII-YB-1F0V77MKUNII-YB 1F0V77MKBenzoic acid, 2-((3S,4R)-3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl)-4-(trifluoromethyl)-2-(3-benzyl–4-hydroxy-chroman–7–yl)–4-trifluoromethyl-benzoic acid2-[ (3S,4R)-4-hydroxy–3-(phenylmethyl)chroman–7–yl ] – 4-(trifluoromethyl)benzoic acid